Author

T. Sanaki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

A. Sato· 4 shared H. Sawa· 4 shared K. Uemura· 4 shared M. Sasaki· 4 shared Y. Orba· 4 shared S. Toba· 3 shared W. W. Hall· 3 shared H. Nobori· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

A. Sato

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19

M. Sasaki, K. Tabata, M. Kishimoto, Y. Itakura, H. Kobayashi, T. Ariizumi, K. Uemura, S. Toba, S. Kusakabe, Y. Maruyama, S. Iida, N. Nakajima, T. Suzuki, S. Yoshida, H. Nobori, , H. Sawa

This study shows that oral S-217622 reduces SARS-CoV-2 viral load and improves recovery in hamsters, with activity against multiple variants.

bioRxiv · Feb 14, 2022Microbiology

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Y. Unoh, S. Uehara, K. Nakahara, H. Nobori, Y. Yamatsu, S. Yamamoto, Y. Maruyama, Y. Taoda, K. Kasamatsu, T. Suto, K. Kouki, A. Nakahashi, S. Kawashima, T. Sanaki, S. Toba, , Y. Tachibana

This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.

bioRxiv · Jan 26, 2022Biochemistry

SARS-CoV-2 bearing a mutation at the S1/S2 cleavage site exhibits attenuated virulence and confers protective immunity

M. Sasaki, S. Toba, Y. Itakura, H. M. Herman M. Chambaro, K. Mai, K. Tabata, K. Intaruck, K. Uemura, T. Sanaki, A. Sato, W. W. Hall, Y. Orba, H. Sawa

This study shows that SARS-CoV-2 variants with mutations at the furin cleavage site are less virulent and induce protective immunity in hamsters.

bioRxiv · Apr 29, 2021Microbiology

SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells

M. Sasaki, K. Uemura, A. Sato, T. Sanaki, K. Maenaka, W. W. Hall, Y. Orba, H. Sawa

This study shows that SARS-CoV-2 variants with mutations at the S1/S2 cleavage site emerge in TMPRSS2-deficient cells, leading to reduced cell tropism and plaque size.

PLOS Pathogens · Jan 21, 2021Peer-reviewedMicrobiology